PaxMedica Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on developing treatments for neurological disorders, has priced its public offering of stocks and warrants. The company has set the price at $1.30 per unit, which includes 5,384,615 shares and accompanying warrants that are immediately exercisable and will expire in five years. The transaction's exclusive placement agent is H.C. Wainwright & Co., with the offering expected to close today.
The company is known for its work in anti-purinergic therapies (APT), with a particular emphasis on PAX-101, an intravenous formulation of suramin intended to treat Autism Spectrum Disorder (ASD) and Human African Trypanosomiasis (HAT). PaxMedica's efforts are supported by specialized teams of experts dedicated to researching and developing new treatments for these and potentially related neurological conditions.
With a strategy that reaches millions through various channels of information dissemination, PaxMedica stands out in the biopharmaceutical industry as a key player in the quest to address complex neurological diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.